Story Stocks^®

Abbott Labs (ABT) announced its acquisition of Exact Sciences (EXAS) for $105/share in cash, representing a 56% premium over the unaffected stock price from Tuesday (Bloomberg reported on a possible deal yesterday), and a $21 bln equity value, or about 5.7x next year's sales. This deal marks ABT's entry into the cancer diagnostics market, leveraging EXAS’s leading products like Cologuard and Oncotype DX, which have shown strong growth, including a 22% rise in screening revenue in EXAS's recent Q3 results.

• Strategically, the deal doubles ABT’s diagnostics total addressable market (TAM) from $60 bln to over $120 bln, positioning it for leadership in personalized, preventative cancer diagnostics.
• EXAS brings a strong product portfolio, scale, innovation culture, and a rich pipeline across cancer screening, therapy selection, and monitoring.
• ABT’s diagnostics growth has faced headwinds from declining COVID-19 testing, with Q3 organic Diagnostics revenue down nearly 8% and COVID-19 testing sales plunging 74%.
• Post-acquisition, ABT’s total diagnostics sales will exceed $12 bln annually, with the deal expected to add 50 bps to total sales growth and 300 bps to diagnostics segment growth.
• The acquisition is expected to be dilutive to adjusted EPS in the first two years (estimated 0.20 in 2026, 0.16 in 2027) but accretive thereafter.
• ABT expects at least $100 mln in annual pre-tax synergies by 2028 to help finance the transaction.
• Gross margins are projected to expand by approximately 100 bps company-wide and 700 bps within diagnostics.
• ABT’s disciplined capital strategy maintains dividend growth and plans to reduce debt over time after the acquisition.

Briefing.com Analyst Insight:

ABT’s acquisition of EXAS strategically rejuvenates its diagnostics growth with a high-potential entry into cancer diagnostics. Despite the premium valuation, favorable growth and margin accretion, along with meaningful synergies and a powerful product pipeline, support a compelling long-term outlook. Execution of integration and expansion into international markets will be pivotal in maximizing the acquisition’s value and positioning ABT as a diversified leader in next-generation diagnostics.